By analyzing a cohort of pediatric patients affected by CD, the current study has demonstrated that the circulating levels of TRAIL are not significantly different in CD patients with respect to those in patients with potential CD or eosinophilic esophagitis, while the circulating levels of TRAIL are significantly lower in patients with CD and concomitant autoimmune disorders when compared with those in CD patients with no such disorders. The gene discussed is TNFSF10; the disease is Autoimmunity.